Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24219876 | 0.77 | LMNA (0.43) | RXFP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22408216 | 0.77 | LMNA (0.52) | RXFP1HSD17B10GRIN1KDM4EMAPT | |
| SCHEMBL29445923 | 0.77 | KEAP1 (0.43) | RXFP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22408290 | 0.77 | KEAP1 (0.43) | RXFP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8913242 | 0.77 | SELL (0.42) | RXFP1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL21983593 | 0.74 | ACHE (0.45) | RXFP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24102931 | 0.74 | ALDH1A1 (0.39) | RXFP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL24037986 | 0.73 | MAOA (0.40) | RXFP1NPC1RAB9AKDM4EMAPT | |
| SCHEMBL3267266 | 0.73 | KDM4E (0.43) | RXFP1HSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL27375824 | 0.73 | KDM4E (0.40) | RXFP1HSD17B10GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1541553-B1 | INDOLINE COMPOUND AND MEDICINAL USE THEREOF | KYOTO PHARMA IND (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-7429612-B2 | Indoline compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| CN-100349868-C | Indoline compound and medical use thereof | KYOTO PHARMA IND (JP) | 2007-11-21 | — | — | CN | disclosed |
| US-20060128787-A1 | Novel indoline compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1681781-A | Novel indoline compound and medicinal use thereof | KYOTO PHARMA IND (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1541553-A1 | NOVEL INDOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0409949-B1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | ICI PLC (GB) | 1994-05-18 | — | — | EP | disclosed |
| US-5185452-A | Antidiabetic agents; aldose reductase inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-09 | — | — | US | disclosed |
| EP-0409949-A1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | ICI PLC (GB) | 1991-01-30 | — | — | EP | disclosed |
| WO-1990008763-A1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128787-A1 | Novel indoline compound and medicinal use thereof | ACAT2, ACAT1, ACOX1 | RXFP1 2989/4885HSD17B10 125/4885GRIN2D 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.